ArticleJACC. Case reports2025
Use of an IL-1 Inhibitor for Refractory Steroid-Dependent Lupus Pericarditis With Constrictive Physiology.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics.Current cardiology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPericardial involvement is common in systemic lupus erythematosus (SLE) and can lead to recurrent episodes. B cell-targeted therapies are commonly used in the treatment of SLE pericarditis. The management of recurrent lupus pericarditis refractory to B cell-targeted therapy remains challenging. CASE SUMMARY: A 33-year-old woman with SLE developed steroid-dependent, recurrent pericarditis with large effusions requiring 2 pericardial windows. Despite corticosteroids, colchicine, hydroxychloroquine, and the B cell-targeted therapy belimumab, she had persistent symptomatic recurrences with features of evolving constrictive physiology on cardiac magnetic resonance. Transition to rilonacept led to rapid symptom resolution, steroid discontinuation, and cardiac magnetic resonance-documented reversal of pericardial inflammation and constrictive physiology. DISCUSSION: This case illustrates that interleukin-1 inhibition with rilonacept can be an effective steroid-sparing strategy for refractory lupus pericarditis after failure of traditional B cell-targeted therapy. TAKE-HOME MESSAGES: Lupus pericarditis can be steroid dependent and refractory to standard SLE immunosuppression, including B cell-directed biologics. Interleukin-1 inhibition offers a potential therapeutic strategy for breaking the autoinflammatory cycle that can sustain recurrent pericarditis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.